Terns reports positive Phase 1 CARDINAL data for TERN-701 in CML; MMR rate 50% at 3 months

Terns Pharmaceuticals, Inc.

15 patients enrolled across 160mg, 320mg, 400mg QD; 14 of 15 remain on treatment as of Oct 28, 2024 cutoff.
Cumulative MMR rate 50% (5/10) in non-T315i patients with ≥3 months treatment or MMR at baseline.
No dose-limiting toxicities, AE-related discontinuations, dose reductions, or Grade 3+ treatment-related AEs.
At 160mg and 320mg, free drug concentrations 4- and 8-fold above efficacious in vivo exposures.
Dose expansion to start 1H25; longer-term MMR data expected in 4Q25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.